FibroGen, Inc. Announces Results Of Phase 2 Study Of FG-3019 Indicating Positive Activity Against Pancreatic Cancer
6/2/2014 9:41:35 AM
CHICAGO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen) today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). In the study, FG-3019 demonstrated a dose-dependent improvement in one-year and overall survival rates, and appeared to be safe and well tolerated. The full data will be presented today at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in a poster session from 8:00 AM to 11:45 AM CDT, Location S Hall A2, Abstract Number 4138.
Help employers find you! Check out all the jobs and post your resume.
comments powered by